Chemical subgroup
L01EE – Mitogen-aktivierte Proteinkinase (MEK)-Inhibitoren
11Decisions
19Patient groups
Added benefit by patient group
- Considerable4
- Minor1
- Non-quantifiable5
- Not proven9
Decisions, newest first
- 2026-08-06KoselugoSelumetinibNon-quantifiable
- 2026-05-07KoselugoSelumetinibMinor
- 2026-05-07KoselugoSelumetinibNon-quantifiable
- 2026-03-19EzmeklyMirdametinibNon-quantifiable
- 2025-03-20MektoviBinimetinibNot proven: 3 of 3 patient groups
- 2024-10-17SpexotrasTrametinibConsiderable: 1 of 3 patient groupsNon-quantifiable: 2 of 3 patient groups
- 2019-03-22MektoviBinimetinibNot proven: 2 of 2 patient groups
- 2019-03-22MekinistTrametinibConsiderable
- 2017-10-19MekinistTrametinibNot proven: 3 of 3 patient groups
- 2016-06-02CotellicCobimetinibConsiderable
- 2016-03-17MekinistTrametinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
Data status: 2026-10-29